[PREVENTX LOGO]

FOR IMMEDIATE RELEASE                                       CONTACT:
                                                            Stephen Phillips or
                                                            Diana Lueptow
                                                            Edward Howard & Co.
                                                            (216) 781-2400

     EMPYREAN BIOSCIENCE LAWSUIT AGAINST INTERNATIONAL BIOSCIENCE CONTINUES

CLEVELAND, May 3, 2000 - Empyrean Bioscience Inc. (OTCBB: EMDG), said today that
its lawsuit against International  Bioscience Corporation (IBC) in U.S. District
Court for the  Southern  District of Florida will  continue  despite the Court's
denial of its request for a preliminary  injunction that would have enjoined IBC
from certain  anticipatory  breaches of its exclusive  licensing  agreement with
Empyrean.  The  Court's  decision  does not  affect  the  merits of the case nor
Empyrean's claim for money damages against IBC, but defers them to a full trial,
which Empyrean expects to be held later this year.

     Empyrean's  claim for the full rights  accorded  to it under the  exclusive
license agreement,  which is the center of the dispute with IBC, will not impact
the  Company's  current  operations.  The Court  observed in its Order,  and IBC
acknowledged  in its pleadings filed with the court,  that Empyrean's  rights to
sell the hand lotion in the United  States and Canada arise from  different  and
separate  agreements with IBC, and such rights are not affected by this lawsuit.
Empyrean said it has sufficient  inventory  levels of Preventx(R) hand sanitizer
and  enjoys  an  outstanding  relationship  with its  supplier,  allowing  it to
continue meeting and exceeding its growing market needs.

     Empyrean - a consumer products company  specializing in innovative personal
care products  designed to prevent the spread of  infectious  diseases - entered
into an exclusive  licensing  agreement  with IBC in February  1998 that enables
Empyrean to develop,  manufacture,  market and  distribute all of IBC's products
throughout  the world,  with the exception of Africa,  Hong Kong and Taiwan.  In
return,  Empyrean  has  asserted  that it  has,  in good  faith,  satisfied  its
requirements under the agreement.

     The company's suit,  which was filed on April 10, 2000 against IBC, seeks a
jury trial and compensatory damages, as well as a declaration that the exclusive
license agreement remains in full force and effect. Following Empyrean's request
for a preliminary  injunction,  IBC purported to terminate the exclusive license
agreement, an issue that will be considered at the full trial. If an unfavorable
decision  were to be rendered  against  Empyrean  at the full trial,  Empyrean's
business could be materially and adversely  affected.  While no assurance can be
given on the ultimate outcome,  management  believes Empyrean will be successful
should a full trial occur. The trial date has not yet been set.

     "Consistent  with the Court's  decision,  we will conduct business as usual
and satisfy market demand for our Preventx(R)  hand  sanitizer," said Richard C.
Adamany,  Empyrean's  president and chief executive officer. "We look forward to
expedited  discovery  and a speedy trial to prove our case that IBC  disregarded
key provisions explicitly spelled out in our exclusive licensing agreement."

     Empyrean  Bioscience is a consumer  products  company  specializing  in the
marketing,  sale and distribution of innovative  personal care products designed
to  prevent  the  spread  of  infectious  diseases.  For more  information,  see
www.empyreanbio.com.

THIS PRESS  RELEASE  INCLUDES  STATEMENTS  THAT MAY  CONSTITUTE  FORWARD-LOOKING
STATEMENTS MADE PURSUANT TO THE SAFE HARBOR PROVISIONS OF THE PRIVATE SECURITIES
LITIGATION  REFORM ACT OF 1995. THE STATEMENTS  REGARDING  "MANAGEMENT  BELIEVES
EMPYREAN  WILL BE  SUCCESSFUL,""CONDUCT  BUSINESS  AS USUAL AND  SATISFY  MARKET
DEMAND" AND "PROVE OUR CASE" ARE FORWARD-LOOKING IN NATURE. THESE STATEMENTS ARE
SUBJECT TO RISKS AND  UNCERTAINTIES  THAT COULD CAUSE  ACTUAL  RESULTS TO DIFFER
MATERIALLY FROM THE FORWARD-LOOKING  STATEMENTS. SUCH RISKS INCLUDE, AMONG OTHER
FACTORS,  THE  ACCEPTABILITY OF THE POTENTIAL PRODUCT IN THE MARKETPLACE AND THE
ABILITY TO OBTAIN  SUFFICIENT  CAPITAL TO FUND OPERATIONS.  ADDITIONAL  FACTORS,
WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER  MATERIALLY FROM  EXPECTATIONS IN THE
FORWARD-LOOKING  STATEMENTS,  ARE SET FORTH IN THE COMPANY'S  FORM 10K-SB ANNUAL
REPORT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                      # # #